JP2015512387A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512387A5
JP2015512387A5 JP2015501721A JP2015501721A JP2015512387A5 JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5 JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015501721 A JP2015501721 A JP 2015501721A JP 2015512387 A5 JP2015512387 A5 JP 2015512387A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
gdf11
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015501721A
Other languages
English (en)
Japanese (ja)
Other versions
JP6124986B2 (ja
JP2015512387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/030140 external-priority patent/WO2013142114A1/en
Publication of JP2015512387A publication Critical patent/JP2015512387A/ja
Publication of JP2015512387A5 publication Critical patent/JP2015512387A5/ja
Application granted granted Critical
Publication of JP6124986B2 publication Critical patent/JP6124986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015501721A 2012-03-19 2013-03-11 拡張期心不全を処置するための増殖分化因子（ｇｄｆ） Active JP6124986B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261612550P 2012-03-19 2012-03-19
US61/612,550 2012-03-19
US201261649962P 2012-05-22 2012-05-22
US61/649,962 2012-05-22
PCT/US2013/030140 WO2013142114A1 (en) 2012-03-19 2013-03-11 Growth differentiation factor (gdf) for treatment of diastolic heart failure

Publications (3)

Publication Number Publication Date
JP2015512387A JP2015512387A (ja) 2015-04-27
JP2015512387A5 true JP2015512387A5 (enExample) 2016-04-07
JP6124986B2 JP6124986B2 (ja) 2017-05-10

Family

ID=49223184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501721A Active JP6124986B2 (ja) 2012-03-19 2013-03-11 拡張期心不全を処置するための増殖分化因子（ｇｄｆ）

Country Status (6)

Country Link
US (1) US9434779B2 (enExample)
EP (1) EP2828289B1 (enExample)
JP (1) JP6124986B2 (enExample)
CA (1) CA2901394A1 (enExample)
ES (1) ES2779698T3 (enExample)
WO (1) WO2013142114A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
WO2015073396A1 (en) * 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
CN106573030A (zh) * 2014-05-16 2017-04-19 因特穆内公司 Lpa相关蛋白和rna表达
WO2016049662A1 (en) * 2014-09-23 2016-03-31 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
EP3224361B1 (en) 2014-11-24 2019-06-19 Somalogic, Inc. Nucleic acid compounds for binding growth differentiation factor 11
US11041006B2 (en) 2015-12-28 2021-06-22 Riken Compositions for use in recovering or ameliorating deterioration of physiological functions due to aging
ES2893813T3 (es) 2016-01-06 2022-02-10 Harvard College El tratamiento con GDF11 previene el aumento de peso, mejora la tolerancia a la glucosa y reduce la hepatoesteatosis
WO2019144053A1 (en) * 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof
US20200222459A1 (en) * 2019-01-16 2020-07-16 Melvin Barnes System, Method and Compositions for Treating Age-Related Illnesses and Conditions
JP2022001603A (ja) * 2021-10-14 2022-01-06 功 加治佐 自分由来ｉＰＳ若い血液応用ＧＤＦ１１分子コーティング若返り経口不老不死薬９
CN114989310B (zh) * 2022-06-20 2024-11-19 深圳先进技术研究院 一种嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及应用
CN115212299B (zh) * 2022-06-21 2026-02-24 深圳先进技术研究院 Car-t和car-m联用在制备抗肿瘤药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4612302A (en) 1983-11-14 1986-09-16 Brigham And Women's Hospital Clinical use of somatostatin analogues
US4684620A (en) 1984-09-04 1987-08-04 Gibson-Stephens Neuropharmaceuticals, Inc. Cyclic polypeptides having mu-receptor specificity
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4853371A (en) 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DK0698094T3 (da) * 1993-05-12 2004-05-03 Inst Genetics Llc BMP-11-sammensætninger
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6008434A (en) * 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2291514C (en) 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20070155661A1 (en) 2003-02-14 2007-07-05 The Board Of Trustees Of The Leland Standord Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2007257208B2 (en) 2006-05-17 2013-05-02 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
WO2009142678A1 (en) 2008-03-27 2009-11-26 Promega Corporatin Protein labeling with cyanobenzothiazole conjugates

Similar Documents

Publication Publication Date Title
EA201791656A1 (ru) Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm)
Damman et al. Pathophysiological mechanisms contributing to renal dysfunction in chronic heart failure
ES2363368T5 (es) Utilización de vitamina K para revertir la calcificación de los vasos sanguíneos
JP2017530954A5 (enExample)
Malhotra et al. 103 prevalence and significance of anterior T wave inversion in females
Pyka et al. Revascularization in ischemic heart failure with reduced left ventricular ejection fraction. The impact of complete revascularization
Datta et al. Apical Hypertrophic Cardiomyopathy and Myocardial Infarction in a Young Adult, a Rare Combination
Gokalp et al. Clinically asymptomatic myocardial bridging in a child with familial subaortic stenosis
Rajeshwari Bilateral absence of common carotid artery with variant branching pattern of aortic arch
Franklin The pathobiology of isolated systolic hypertension
Madias Coronary artery systolic “milking” and “bridging” in Takotsubo syndrome: substrate or an epiphenomenon?
Aimo Surgical Anatomy of Coronary Arteries: Morphogenesis, Normal and Pathological Anatomy
Savinova Myostatin Expression in the Heart is Temporally and Regionally Distinct
Ahmed et al. Late stent fracture-A potential role of left ventricular dilatation
Kraiem et al. P4718 Follow up in heart failure center versus routine practice: which positive impact we can have?
Hayashi et al. P3293 One year result of the underfilling strategy in transcatheter aortic valve implantation with balloon expandable valve
Graziani et al. Severe silent myocardial ischemia during echocardiographic examination in a patient during cardiac screening for a kidney transplant intervention
Otsuka et al. Gender differences between left and right ventricular diastolic function in normal subjects
Wenzelburger et al. Torsional dyssynchrony on exercise is linked to left ventricular hypertrophy in patients with heart failure and preserved ejection fraction
Valencia et al. C56 CLINICAL CASES IN PULMONARY VASCULAR MEDICINE: Levoatriocardinal Vein: An Unusual Cause Of Hypoxemia In The Intensive Care Unit
Sillanmaki et al. P1563 Relationships between electrical and mechanical dyssynchrony in patients with left bundle branch block
Mizukoshi et al. Diastolic strain rate affects exercise capacity in patients with hypertrophic cardiomyopathy
Sugiura et al. P729 Differential effects of peripheral and central blood pressures on circulating levels of high-sensitivity cardiac troponin I
Ibe et al. Pulmonary hypertension in patients with left heart disease: the relationship with left ventricular systolic function
Goudot et al. P731 Carotid elastic properties impairment in case of Bicuspid aortic valve: myth or reality?